Pricing:

Single User Licence
$4200
Multi User License Upto 5 Users
$6500
Enterprise License
$8400
Download Sample Add to Cart Buy Now

Don’t see what you are Looking For:

We can create a custom report for you, please fill the form below

Global Chordoma Disease Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Diagnosis;

Biopsy, Imaging & X-Ray(Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scan, Positron Emission Tomography (PET) Scanning & Bone Scan), Blood Tests, and Others.

By Treatment;

Chemotherapy(Methotrexate, Doxorubicin, and Others), Radiation Therapy, Cryosurgery & Surgical Treatments(Radical Resections, Sacral Chordoma, Spinal Chordoma, Skull Base Chordoma, and Others), Radiosurgery, Targeted Therapy(Bevacizumab, Erlotinib, and Others), and Others.

By End User;

Hospital, Clinic, and Cancer Care Centers.

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031).

Report ID: Rn357778459 Published Date: March, 2025 Updated Date: April, 2025

Download Free Sample Now Request Customized Sample

Introduction

Global Chordoma Disease Market (USD Million), 2021 - 2031

In the year 2024, the Global Chordoma Disease Market was valued at USD 4,526.62 million. The size of this market is expected to increase to USD 12,494.86 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 15.6%.

The global chordoma disease market is a specialized segment of the healthcare industry focused on the diagnosis, treatment, and management of chordoma, a rare type of cancer that occurs in the bones of the skull base and spine. The market's growth is driven by several factors, including advancements in medical research, increased awareness of rare cancers, and improved diagnostic techniques. As a result, healthcare providers are better equipped to identify chordoma in its early stages, leading to more effective treatment outcomes. The market encompasses a range of products and services, from diagnostic imaging tools and biopsy kits to various therapeutic approaches, such as surgery, radiation therapy, and emerging targeted therapies.

Despite being a rare disease, the chordoma market has seen significant developments due to collaborative efforts among researchers, pharmaceutical companies, and patient advocacy groups. These collaborations have facilitated the development of innovative treatment modalities and clinical trials aimed at finding more effective therapies with fewer side effects. Regulatory incentives for orphan diseases have encouraged pharmaceutical companies to invest in chordoma research. The market is poised for continued growth as ongoing research efforts and technological advancements lead to improved patient care and outcomes. The increasing incidence of chordoma cases globally underscores the need for enhanced treatment options and comprehensive management strategies, further driving the market's expansion.

Global Chordoma Disease Market Recent Developments

In April 2023, Foundation Medicine broadened its partnership with Natera to integrate Natera’s liquid biopsy technology with FoundationOne CDx, enhancing comprehensive genomic profiling for cancer patients. This collaboration aims to improve diagnostics and treatment options across various cancers, including chordoma
In March 2023, Bayer's subsidiary Loxo Oncology began phase II trials for LOXO-292 (selpercatinib), targeting RET-altered tumors. This research supports Bayer’s efforts to explore genetic and molecular abnormalities across cancers, including chordoma, aiming to advance targeted therapies for improved patient outcomes.

Segment Analysis

The global chordoma disease market is segmented based on diagnosis, treatment, and end user, each contributing to its growing scope. In terms of diagnosis, the market is driven by various techniques such as biopsy, imaging methods, and blood tests. Imaging tools like magnetic resonance imaging (MRI), computed tomography (CT) scans, positron emission tomography (PET) scanning, and bone scans are crucial for detecting chordomas, while biopsy is often used for confirmation of the disease. Blood tests and other diagnostic methods are also employed to aid in the detection and monitoring of chordoma progression. As these diagnostic techniques evolve, they contribute significantly to the early identification and management of chordoma, fostering market expansion.

The treatment segment of the chordoma market includes chemotherapy, radiation therapy, cryosurgery, and various surgical options. Chemotherapy drugs such as methotrexate and doxorubicin are commonly prescribed, though treatment regimens may vary. Radiation therapy is another key option for chordoma patients, with advanced techniques improving outcomes. Cryosurgery, along with different surgical treatments such as radical resections and treatments for sacral, spinal, and skull base chordomas, remains a mainstay in patient care. Furthermore, radiosurgery and targeted therapies, including bevacizumab and erlotinib, have gained attention due to their potential to improve patient outcomes by specifically targeting cancer cells, which drives innovation in treatment methodologies.

The end-user segment highlights hospitals, clinics, and cancer care centers as the primary settings for chordoma diagnosis and treatment. Hospitals are often the most equipped to handle complex chordoma cases, with advanced diagnostic equipment and multidisciplinary teams. Clinics and cancer care centers also play an essential role in providing specialized care and follow-up treatment for patients. These end users are critical in ensuring the availability of chordoma treatments to a broader patient population, enhancing access to care across regions, which, in turn, supports market growth.

Overall, the global chordoma disease market is expanding due to advances in diagnostic technologies, innovative treatment options, and the increasing number of healthcare facilities dedicated to cancer care. As research continues to progress, new therapies and improved diagnostic methods are expected to play a key role in shaping the market. Additionally, the rising prevalence of chordoma and awareness of available treatments will likely increase demand for both specialized care centers and the latest therapeutic solutions, further boosting market growth.

Global Chordoma Disease Segment Analysis

In this report, the Global Chordoma Disease Market has been segmented by Diagnosis, Treatment, End User and Geography.

Global Chordoma Disease Market, By Diagnosis

The Global Chordoma Disease Market has been segmented by Diagnosis into Biopsy, Imaging, X-Ray, Blood Tests and Others.

Biopsies are one such critical tool, involving the extraction of tissue samples for microscopic examination to identify abnormalities such as cancerous cells. Imaging and X-ray technologies also play a pivotal role in diagnosis. Magnetic Resonance Imaging (MRI) uses strong magnetic fields and radio waves to create detailed images of organs and tissues, which is particularly useful for soft tissue evaluation, such as in the brain, muscles, and connective tissues. Computed Tomography (CT) scans combine X-ray measurements taken from different angles to produce cross-sectional images, offering a comprehensive view of areas like the chest, abdomen, and pelvis. Positron Emission Tomography (PET) scanning is a type of nuclear medicine imaging that assesses metabolic and biochemical activity, often used to detect cancer and monitor its treatment.

Bone scans, another form of nuclear imaging, specifically identify bone abnormalities by using radioactive tracers. Blood tests are another cornerstone of medical diagnostics, providing critical information about the biochemical and physiological state of the body. These tests can detect markers of disease, such as elevated white blood cell counts in infections or specific enzymes and proteins related to organ function. For instance, blood glucose levels are monitored for diabetes, while lipid profiles assess cardiovascular health. Other diagnostic techniques include genetic testing, which can identify inherited conditions and predispositions to certain diseases.

Global Chordoma Disease Market, By Treatment

The Global Chordoma Disease Market has been segmented by Treatment into Chemotherapy, Radiation Therapy, Cryosurgery, Surgical Treatments, Radiosurgery, Targeted Therapy and Others.

Chemotherapy, while a common cancer treatment, is less frequently used for chordoma due to its limited efficacy in treating this type of tumor. Instead, radiation therapy is often employed, either as a primary treatment or adjunctively post-surgery, to target residual tumor cells and reduce the risk of recurrence. Advanced techniques such as proton beam therapy are preferred due to their precision in sparing surrounding healthy tissues. Cryosurgery, although less common, offers a minimally invasive option by using extreme cold to destroy cancer cells, which can be beneficial for certain patients.

Surgical treatments remain the cornerstone of chordoma management, aiming for complete resection of the tumor. The complexity of chordomas, often located at the base of the skull or along the spine, necessitates highly specialized surgical expertise to maximize removal while minimizing damage to critical structures. Radiosurgery, including techniques like Gamma Knife and CyberKnife, provides a non-invasive option that delivers high doses of radiation precisely to the tumor site. Targeted therapy represents a growing segment, focusing on molecular and genetic profiles of the tumor to disrupt specific pathways critical for tumor growth and survival. Other emerging treatments and supportive therapies are also being explored to enhance patient outcomes and quality of life, reflecting the diverse and evolving landscape of chordoma disease management.

Global Chordoma Disease Market, By End User

The Global Chordoma Disease Market has been segmented by End User into Hospital, Clinic, and Cancer Care Centers.

The global chordoma disease market is divided into several key end-user segments, with hospitals being one of the largest contributors. Hospitals play a critical role in the treatment of chordoma due to their comprehensive medical infrastructure, advanced diagnostic tools, and access to highly skilled specialists. As chordoma is a rare and complex cancer, hospitals offer multidisciplinary care, including surgery, radiation therapy, and palliative care, making them essential in managing this condition.

Clinics also represent a significant segment in the chordoma disease market. While they may not have the extensive resources of hospitals, specialized clinics provide targeted care for chordoma patients, often focusing on specific treatments like radiation or follow-up care. These clinics tend to offer more personalized services, including consultations with oncologists and genetic counselors, which are vital for the management of rare cancers such as chordoma.

Cancer care centers have emerged as another important segment in the chordoma market. These centers specialize in treating various forms of cancer, including rare types like chordoma. They provide a range of treatment options, such as advanced surgical procedures, proton therapy, and clinical trials for experimental therapies. Their expertise in managing cancer patients makes them key players in improving outcomes for those diagnosed with chordoma, offering patients access to the latest treatments and therapies.

Global Chordoma Disease Market, By Geography

In this report, the Global Chordoma Disease Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Chordoma Disease Market Share (%), by Geographical Region, 2024

North America, encompassing the United States and Canada, stands as a significant segment due to advanced healthcare infrastructure, high awareness, and substantial investment in research and development for rare diseases. Europe follows closely, driven by robust healthcare systems, significant government support, and active collaborations between research institutions and pharmaceutical companies. The presence of established market players and continuous innovation also contribute to the prominence of these regions in the chordoma disease market.

The Asia Pacific region, covering major economies such as China, Japan, and India, is emerging as a rapidly growing segment due to increasing healthcare expenditure, improving medical facilities, and growing awareness about rare diseases. The Middle East and Africa, while currently exhibiting a smaller market size, show potential for growth driven by rising healthcare investments and initiatives to enhance medical research. Latin America is witnessing gradual progress in market development with improving healthcare access and rising focus on rare diseases. Each of these regions presents unique opportunities and challenges, shaping the overall dynamics and future trajectory of the global chordoma disease market.

Market Trends

This report provides an in depth analysis of various factors that impact the dynamics of Global Chordoma Disease Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

Improved diagnostic techniques
Increasing prevalence of chordoma
Expanding biotechnology sector
Availability of specialized treatments - The availability of specialized treatments for chordoma is a significant driver in the market, as these tailored therapies offer more effective and targeted management of the disease. Unlike conventional treatments, which may not address the unique characteristics of chordoma, specialized treatments such as proton beam therapy, targeted radiation, and advanced surgical techniques provide better outcomes with fewer side effects.

These innovative treatments are often developed through extensive research and clinical trials, leading to a higher success rate in managing this rare and challenging cancer. As more healthcare providers adopt these specialized treatments, patients benefit from improved quality of life and survival rates, thereby driving the demand and growth of the chordoma disease market.

Restraints

Side effects of treatments
Delayed diagnosis
Slow adoption of new technologies - Despite the potential benefits of new technologies in diagnosing and treating chordoma, their adoption remains slow due to several barriers. High costs associated with advanced technologies can deter healthcare facilities, particularly in resource-limited settings, from integrating them into their practice. The need for specialized training to operate new equipment and interpret complex data can delay implementation.

There is also a degree of skepticism and resistance to change among healthcare professionals who are accustomed to traditional methods. This slow adoption hinders the potential progress in improving patient outcomes and limits the market growth, as innovations that could revolutionize treatment are not fully utilized.

Opportunities

Advancements in genomic research
Development of new treatment modalities
Growing patient advocacy groups
Development of orphan drugs - The development of orphan drugs for chordoma represents a significant opportunity within the global market. Orphan drugs are specifically designed to treat rare diseases, and their development is often supported by regulatory incentives such as extended market exclusivity, tax credits, and grant funding. For pharmaceutical companies, investing in orphan drugs can be financially viable due to these incentives and the potential for premium pricing.

These drugs can address unmet medical needs, offering new hope to patients with limited treatment options. As research advances and more orphan drugs are developed and approved, the chordoma disease market is poised to benefit from increased therapeutic options, enhancing patient care and expanding market opportunities for pharmaceutical companies.

Competitive Landscape Analysis

Key players in Global Chordoma Disease Market include

GlaxoSmithKline Plc
Pfizer, Inc.
Merck & Co., Inc.
Sanofi Pasteur SA
Astellas Pharma Inc.
CSL Limited
Emergent BioSolutions, Inc.
Johnson & Johnson

In this report, the profile of each market player provides following information:

Company Overview and Product Portfolio
Key Developments
Financial Overview
Strategies
Company SWOT Analysis

Introduction
1. Research Objectives and Assumptions
2. Research Methodology
3. Abbreviations
Market Definition & Study Scope
Executive Summary
1. Market Snapshot, By Diagnosis
2. Market Snapshot, By Treatment
3. Market Snapshot, By End User
4. Market Snapshot, By Region
Global Chordoma Disease Market Dynamics
1. Drivers, Restraints and Opportunities
  1. Drivers
    1. Improved diagnostic techniques
    2. Increasing prevalence of chordoma
    3. Expanding biotechnology sector
    4. Availability of specialized treatments
  2. Restraints
    1. Side effects of treatments
    2. Delayed diagnosis
    3. Slow adoption of new technologies
  3. Opportunities
    1. Advancements in genomic research
    2. Development of new treatment modalities
    3. Growing patient advocacy groups
    4. Development of orphan drugs
2. PEST Analysis
  1. Political Analysis
  2. Economic Analysis
  3. Social Analysis
  4. Technological Analysis
3. Porter's Analysis
  1. Bargaining Power of Suppliers
  2. Bargaining Power of Buyers
  3. Threat of Substitutes
  4. Threat of New Entrants
  5. Competitive Rivalry
Market Segmentation
1. Global Chordoma Disease Market, By Diagnosis, 2021 - 2031 (USD Million)
  1. Biopsy
  2. Imaging & X-Ray
    1. Magnetic Resonance Imaging (MRI)
    2. Computed Tomography (CT) Scan
    3. Positron Emission Tomography (PET) Scanning
    4. Bone Scan
  3. Blood Tests
  4. Others
2. Global Chordoma Disease Market, By Treatment, 2021 - 2031 (USD Million)
  1. Chemotherapy
    1. Methotrexate
    2. Doxorubicin
    3. Others
  2. Radiation Therapy
  3. Cryosurgery
  4. Surgical Treatments
    1. Radical Resections
    2. Sacral Chordoma
    3. Spinal Chordoma
    4. Skull Base Chordoma
    5. Others
  5. Radiosurgery
  6. Targeted Therapy
    1. Bevacizumab
    2. Erlotinib
    3. Others
  7. Others
3. Global Chordoma Disease Market, By End User, 2021 - 2031 (USD Million)
  1. Hospital
  2. Clinic
  3. Cancer Care Centers
4. Global Chordoma Disease Market, By Geography, 2021 - 2031 (USD Million)
  1. North America
    1. United States
    2. Canada
  2. Europe
    1. Germany
    2. United Kingdom
    3. France
    4. Italy
    5. Spain
    6. Nordic
    7. Benelux
    8. Rest of Europe
  3. Asia Pacific
    1. Japan
    2. China
    3. India
    4. Australia & New Zealand
    5. South Korea
    6. ASEAN (Association of South East Asian Countries)
    7. Rest of Asia Pacific
  4. Middle East & Africa
    1. GCC
    2. Israel
    3. South Africa
    4. Rest of Middle East & Africa
  5. Latin America
    1. Brazil
    2. Mexico
    3. Argentina
    4. Rest of Latin America
Competitive Landscape Analysis
1. Company Profiles
  1. GlaxoSmithKline Plc
  2. Pfizer, Inc.
  3. Merck & Co., Inc.
  4. Sanofi Pasteur SA
  5. Astellas Pharma Inc.
  6. CSL Limited
  7. Emergent BioSolutions, Inc.
  8. Johnson & Johnson
Analyst Views
Future Outlook of the Market